GlassScriptPhysician profile
Lauren Gesell
NPI 1083210678
$4,580.35
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $1,241 · 2023: $2,312 · 2024: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.60 |
| Education | $292.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $565.67 | 2021-2023 | Imfinzi, Lynparza |
| Lilly USA, LLC | $453.03 | 2022-2024 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $330.78 | 2021-2024 | |
| Abbvie INC. | $265.76 | 2023-2024 | |
| Janssen Biotech, INC. | $196.03 | 2021-2024 | Darzalex, Tecvayli, Imbruvica |
| Daiichi Sankyo INC. | $174.58 | 2021-2023 | Injectafer |
| Incyte Corporation | $170.84 | 2021-2024 | Jakafi |
| Merck Sharp & Dohme LLC | $156.00 | 2022-2023 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $139.18 | 2023-2024 | Ninlaro, Fruzaqla, Alunbrig |
| Genentech USA, INC. | $132.75 | 2022-2023 | Kadcyla, Phesgo, Perjeta |
| Amgen INC. | $124.69 | 2022-2023 | Kyprolis |
| G1 Therapeutics, INC. | $118.53 | 2022-2023 | Cosela |
| Mirati Therapeutics, INC. | $117.55 | 2023-2024 | Krazati |
| Eisai INC. | $107.51 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $101.63 | 2022-2024 | Libtayo |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Gesell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.